Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.
Type:
Application
Filed:
January 26, 2016
Publication date:
January 18, 2018
Applicant:
Rhode Island Hospital, A Lifespan Partner
Inventors:
Gregory D. Jay, Benjamin D. Sullivan, Tannin Avery Schmidt, Khaled Elsaid, Edward R. Truitt, Roman Krawetz, Joanna Szmydynger-Chodobska, Adam Chodobska, Jawed Fareed
Abstract: A method for preventing, slowing, or blocking the formation of an exostosis or an enchondromas comprising administering to an animal in need thereof a hedgehog pathway inhibitor such as a Smoothened inhibitor.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
December 5, 2017
Assignees:
Rhode Island Hospital, University Health Network
Abstract: The specification provides methods of determining whether a subject suffering from ER+/HER2+ breast cancer is likely to respond to adjuvant and neoadjuvant chemotherapy and methods of treating a subject suffering from ER+/HER2+ breast cancer.
Type:
Grant
Filed:
June 20, 2016
Date of Patent:
October 10, 2017
Assignee:
Rhode Island Hospital, A Lifespan-Partner
Inventors:
Alexander S. Brodsky, Yihong Wang, Murray Resnick
Abstract: The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis.
Type:
Grant
Filed:
March 16, 2015
Date of Patent:
October 3, 2017
Assignee:
Rhode Island Hospital
Inventors:
Qian Chen, Yupeng Chen, Hongchuan Yu, Michael G. Ehrlich
Abstract: A device for assembling aggregations of adherent cells includes a gripper moveable within an assembly vessel that fixes aggregations of adherent cells at a membrane of the gripper and, by movement of the gripper, assembles aggregations of cells on a separate membrane within the vessel, thereby creating a three-dimensional assembly of aggregations of cells that fuse and can be employed in surgical procedures as a unitary tissue of adherent cells. The aggregations of cells, as assembled, can assume three-dimensional configurations distinct from any one of the component aggregations of cells assembled.
Type:
Grant
Filed:
July 11, 2014
Date of Patent:
September 26, 2017
Assignees:
Brown University, Rhode Island Hospital
Inventors:
Jeffrey R. Morgan, Andrew Blakely, John Murphy, Anubhav Tripathi, William Patterson
Abstract: The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydroxylase (e.g., Asparatyl (asparaginyl) ?-hydroxylase (ASPH)), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.
Type:
Grant
Filed:
September 20, 2013
Date of Patent:
September 26, 2017
Assignees:
Rhode Island Hospital, Midwestern University
Inventors:
Jack R. Wands, Suzanne De La Monte, Arihiro Aihara, Mark Jon Olsen, John-Michael Thomas
Abstract: This invention relates to methods for treating, preventing, or reversing liver disease or damage produced by chronic alcohol intake by administering at least one peroxisome proliferator activated receptor (PPAR) agonist.
Type:
Grant
Filed:
September 10, 2007
Date of Patent:
August 1, 2017
Assignee:
Rhode Island Hospital
Inventors:
Suzanne Marie de la Monte, Jack Raymond Wands
Abstract: A thermal accelerant is delivered to a tissue site and localized to modulate the shape, extent or other characteristic of RF or microwave-induced hyperthermic tissue ablation. The accelerant may be provided via an image-guided hand piece or via a lumen added to a microwave antenna, and promotes faster heating, more complete ablation and/or a more extensive treatment region to reduce recurrence of treated cancers, overcoming natural limitations, variations in tissue response and drop-off or thermal loss away from the antenna. The accelerant is delivered as a low-viscosity but heat sensitive fluid, and is fixed in place to provide regions of preferential absorption or heating. Shorter exposure times to heat the far field may allow survival of vulnerable tissue such as vessels, and multiple antennae may be used for effective treatment of irregular or large tumors.
Type:
Application
Filed:
December 23, 2016
Publication date:
June 29, 2017
Applicants:
RHODE ISLAND HOSPITAL, BROWN UNIVERSITY
Inventors:
William Keun Chan Park, Damian E. Dupuy, Edward G. Walsh
Abstract: A vaccine containing AAH-loaded mature dendritic cells for treatment of AAH-expressing tumors in mammalian subjects. A method of producing primed dendritic cells is carried out by contacting isolated dendritic cells with an antigen such as AAH. Following the antigen-contacting step, the dendritic cells are contacted with a combination of cytokines such as GM-CSF and IFN-?.
Abstract: A fixation device including a base structure such as a faceplate having an inferior surface capable of contacting a surface of a skull of a patient, having a superior surface, and defining at least two securement features. Each securement feature can be engaged by a cranial fastener to attach the faceplate to the skull. The device further includes a fixation structure such as an alignment plate or a flexible fixation member carried by the base structure and positionable at least one of (i) over an opening in the skull and (ii) within an opening in the skull. At least one surface of the fixation structure defines at least one channel in which an intracranial device is capable of being placed, and further defines at least one fixation feature to enable the intracranial device to be secured to the fixation device.
Type:
Grant
Filed:
October 30, 2014
Date of Patent:
June 13, 2017
Assignees:
BROWN UNIVERSITY, RHODE ISLAND HOSPITAL
Abstract: Provided herein are methods for prophylactic treatment of renal disorders comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing a renal disorder.
Type:
Grant
Filed:
June 24, 2014
Date of Patent:
January 24, 2017
Assignees:
QUESTCOR PHARMACEUTICALS, INC., RHODE ISLAND HOSPITAL
Abstract: Detection and quantification of microbial colonization and biofilm formation on orthopaedic explants would be important for deciding treatment interventions at the time of surgery. Methods and Systems for such treatments are shown that utilize various steps and kits to quickly generate confocal laser-scanning microscopy (CLSM) images to allow for the detection and quantification. The explants are prepared by applying antibodies of both gram-positive and grain-negative for at least one period of time.
Type:
Application
Filed:
December 17, 2015
Publication date:
December 22, 2016
Applicant:
RHODE ISLAND HOSPITAL
Inventors:
Dioscaris Garcia, Christopher T. Born, John Jarrell
Abstract: Methods and compositions for determining a prognosis for a subject infected with HIV, reducing a risk of an HIV infection, and treating or reducing a risk of developing AIDS are described.
Type:
Grant
Filed:
January 18, 2013
Date of Patent:
December 20, 2016
Assignee:
Rhode Island Hospital, A Lifespan-Partner
Inventors:
Michelle Lally, Bharat Ramratnam, Ming Li
Abstract: Data characterizing a signal of electrical activity sensed in a patient can be received using at least one data processor. A pain signature associated with peripheral nerve damage can be detected using the received data. A treatment protocol can be determined in response to the detected pain signature. The treatment protocol can include providing at least one electrical signal to the patient comprising one or more electrical pulses being at least about 150 Hz, between about 1 and about 3 volts, between about 1 and about 3 milliampere, and between about 0.25 and about 1 second in duration. The treatment protocol to be delivered to a sensory thalamus contained within the patient via an electrical lead and electrode implantable within the sensory thalamus. The treatment protocol can be caused to be initiated.
Abstract: Methods, compositions, systems, devices and kits are provided herein for preparing and using a nanoparticle composition and spatial frequency heterodyne imaging for visualizing cells or tissues. In various embodiments, the nanoparticle composition includes at least one of: a nanoparticle, a polymer layer, and a binding agent, such that the polymer layer coats the nanoparticle and is for example a polyethylene glycol, a polyelectrolyte, an anionic polymer, or a cationic polymer, and such that the binding agent that specifically binds the cells or the tissue. Methods, compositions, systems, devices and kits are provided for identifying potential therapeutic agents in a model using the nanoparticle composition and spatial frequency heterodyne imaging.
Type:
Application
Filed:
April 1, 2016
Publication date:
September 22, 2016
Applicants:
Brown University, Rhode Island Hospital
Inventors:
Christoph Rose-Petruck, Jack R. Wands, Danielle Rand, Zoltan Derdak, Vivian Ortiz
Abstract: Disclosed herein are compositions and methods for detecting nonalcoholic steatohepatitis (NASH) measuring CHI3L1 levels. In some embodiments, the methods described herein can distinguish NASH from nonalcoholic fatty liver disease. CHI3L1 levels can also be used to monitor treatment progress in patients having NASH. Also disclosed herein are compositions and methods for treating NASH by targeting CHI3L1.
Type:
Application
Filed:
November 19, 2015
Publication date:
May 19, 2016
Applicants:
BROWN UNIVERSITY, RHODE ISLAND HOSPITAL, YALE UNIVERSITY
Inventors:
Jack A. ELIAS, Jack R. WANDS, Chun Geun LEE, Kittichai PROMRAT